Ghesquières, Hervé <br/><br/>
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.  [electronic resource] 

 -  Blood  Sep 2012 
 - 2650-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2012-05-431825  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antineoplastic Agents--therapeutic use<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>International Agencies<br/>Lymphoma, Follicular--drug therapy<br/>Male<br/>Middle Aged<br/>Polymorphism, Single Nucleotide--genetics<br/>Prognosis<br/>Prospective Studies<br/>Receptors, IgG--genetics<br/>Remission Induction<br/>Rituximab<br/>Survival Rate